Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2006 pp 499–511Cite as

Betarezeptorenblocker

  • Chapter

  • 420 Accesses

Auszug

Betarezeptorenblocker spielen eine wichtige Rolle bei der Behandlung kardiovaskulärer Erkrankungen. Hauptindikationen sind arterielle Hypertonie, koronare Herzkrankheit, tachykarde Herzrhythmusstörungen und chronische Herzinsuffizienz. Wichtigste Gruppe sind die β1-selektiven Betarezeptorenblocker.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bell DS, Lukas MA, Holdbruck FK, Fowler MB (2006): The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. Curr Med Res Opin 22: 287–296.

    Article  PubMed  CAS  Google Scholar 

  • Bristow MR (2000): β-Adrenergic receptor blockade in chronic heart failure. Circulation 101: 558–569.

    PubMed  CAS  Google Scholar 

  • Bowman AJ, Chen CP, Ford GA (1994): Nitric oxide mediated venodilator effects of nebivolol. Brit J Clin Pharmacol 38: 199–204.

    CAS  Google Scholar 

  • Brodde OE (1991): Beta 1-and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242.

    PubMed  CAS  Google Scholar 

  • Chobanian AV, Bakris GL, Black HR, et al (2003): Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7). Hypertension 42: 1206–1252. http://www.nhlbi.nih.gov/guidelines/hypertension/.

    Article  PubMed  CAS  Google Scholar 

  • CIBIS II Study (1999): The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet 353: 9–13.

    Article  Google Scholar 

  • Cockcroft JR (2005): Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens 18: 177S–183S.

    Article  PubMed  CAS  Google Scholar 

  • Dargie HJ (2003): β-Blockers in heart failure. Lancet 362: 2–3.

    Article  PubMed  Google Scholar 

  • Deutsche Liga zur Bekämpfung des hohen Blutdrucks/Deutsche Hochdruckliga (2003): Leitlinien für die Prävention, Erkennung, Diagnostik und Therapie der arteriellen Hypertonie. http://www.paritaet.org/hochdruckliga/Leit2003.htm.

    Google Scholar 

  • Eschenhagen T (2004): Herzinsuffizienz. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Heidelberg New York, S. 223–258.

    Google Scholar 

  • Flather MC, Shibata MC, Coats AJS et al (2005): Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure. Eur Heart J 26: 215–225.

    Article  PubMed  CAS  Google Scholar 

  • Frishman WH, Kostis J, Strom J, Hossler M, Ekayam U et al (1979): Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 6: A comparison of pindolol and propranolol in the treatment of patients with angina pectoris. The role of intrinsic sympathomimetic activity. Am Heart J 98: 526–535.

    Article  PubMed  CAS  Google Scholar 

  • Grozmann RJ, Garcia-Tsao G, Bosch J et al. (2005): Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353: 2254–2261.

    Article  Google Scholar 

  • Ijzerman AP, Soudijn W (1989): The antiarrhythmic properties of b-adrenoceptor antagonists. Trends Pharmacol Sci 10: 31–36.

    Article  PubMed  CAS  Google Scholar 

  • Lindholm LH, Carlberg B, Samuelsson O (2005): Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366: 1545–1553.

    Article  PubMed  CAS  Google Scholar 

  • Kilbinger H, Rahn K-H (2004): Hypertonie. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer, Berlin Heidelberg New York, S. 209–226.

    Google Scholar 

  • McMurray J (2005): Making sense of SENIORS. Eur Heart J 26: 203–206.

    Article  PubMed  CAS  Google Scholar 

  • MERIT-HF Study (1999): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure. Lancet 353: 2001–2007.

    Article  Google Scholar 

  • Packer M, Coats AJS, Fowler MB, Katus HA et al (2001): Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651–1658.

    Article  PubMed  CAS  Google Scholar 

  • Pesant Y, Marc-Aurele J, Bielmann P, Alaupovic P, Cartier P, Bichet D, et al (1999): Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Am J Ther 6: 137–147.

    Article  PubMed  CAS  Google Scholar 

  • Poirier L, Cléroux J, Nadeau A, Lacourcière Y (2001): Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 19: 1429–1435.

    Article  PubMed  CAS  Google Scholar 

  • Poole-Wilson PA, Svedberg K, Cleland JGF, Lenarda A, Hanrath P, Komajda M et al (2003): Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362: 7–13.

    Article  PubMed  CAS  Google Scholar 

  • Poynard T, Calès P, Pasta L, Ideo G, Pascal J-P et al and the Franco-Italian Multicenter Study Group (1991): Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med 324: 1532–1538.

    Article  PubMed  CAS  Google Scholar 

  • Quyyumi AA, Wright C, Mockus L, Fox KM (1984): Effect of partial agonist activity in β-blockers in severe angina pectoris: A double blind comparison of pindolol and atenolol. Brit Med J 289: 951–953.

    Article  CAS  Google Scholar 

  • Ruf G, Trenk D, Jahnchen E, Roskamm H (1994): Determination of the anti-ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol 43: 279–285.

    Article  PubMed  CAS  Google Scholar 

  • Sackner-Bernstein J (2005): Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy. Clin Cardiol 28(11 Suppl 1): I19–27.

    PubMed  Google Scholar 

  • Salpeter S, Ormiston T, Salpeter E, Wood-Baker R (2006): Cardioselective beta-blockers for reversible airway disease. The Cochrane Library, The Cochrane Collaboration Volume (1), 2006.

    Google Scholar 

  • Schrör K, Kelm M (2004): Koronare Herzkrankheit. In: Lemmer B, Brune K (Hrsg): Pharmakotherapie — Klinische Pharmakologie, 12. Auflage, Springer Verlag, Berlin Heidelberg New York, S. 259–275.

    Google Scholar 

  • Tzemos N, Lim PO, MacDonald TM (2001): Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104: 511–514.

    PubMed  CAS  Google Scholar 

  • Van Nueten L, Taylor FR, Robertson JI (1998): Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 12: 135–140.

    Article  PubMed  CAS  Google Scholar 

  • Weber MA (2005): The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 18:169S–176S.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie und Toxikologie, Fakultät für Klinische Medizin Mannheim, Universität Heidelberg, Maybachstraße 14-16, 68169, Mannheim

    Prof. Dr. med. Dr. h.c. Björn Lemmer

Authors
  1. Prof. Dr. med. Dr. h.c. Björn Lemmer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Lemmer, B. (2007). Betarezeptorenblocker. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation